国产99热精品_欧美疯狂做受xxxx猛交_婷婷在线网站_日韩无遮挡毛片_欧美高清momspuss_欧美激情福利

Horizon Diagnostics  
基因診斷生物標(biāo)志物研發(fā)商Horizon Diagnostics,肺癌生物標(biāo)志物的基因定義的參考標(biāo)準(zhǔn)。參照材料主要用于最大限度地減少FISH和 IHC診斷檢測(cè)中的變異性，用來(lái)指導(dǎo)靶向癌癥治療的用藥。
 

Horizon Diagnostics (HDx), a business unit of Horizon Discovery Ltd, is the world’s first provider of genetically defined, human genomic reference standards, including FFPE cell line blocks, and purified gDNA. These standards offer a sustainable source of reference material to laboratories, proficiency schemes, and manufacturers, and provide an unprecedented level of control.

Variability in DNA extraction from tumour biopsies and a lack of standardisation are currently major sources of error in molecular laboratories. The availability of genetically defined reference standards will provide an industry standard for development and quality control of molecular assays, directly improving their accuracy.

Horizon Diagnostics suite of reference material includes standards for the increasing number of ‘rare’ mutations being targeted for cancer therapeutics, which by definition are hard to find in clinical samples. Drawing upon Horizon Discovery’s proprietary genome editing technology, GENESIS?, HDx reconstitutes clinically relevant cancer genes in human cell lines, exactly as they occur in a patient’s tumour. This technology approach enables HDx to define virtually every characteristic of its reference standards, from the molecular constitution of the genome, to the diameter, width and DNA output associated with each product batch. HDx is also adapting its technology to serve immunohistochemistry (IHC) and fluorescent in-situ hybridisation (FISH) based assays.

Company Details:
Horizon Discovery Ltd.
VAT No: GB 916 6667 90
Registered in England: 05363294
Registered Office: Building 7100, Cambridge Research Park, Cambridge, CB25 9TL, United Kingdom

 

Horizon was founded in 2007 by Dr Chris Torrance and Professor Alberto Bardelli and builds upon a 20 year heritage in oncology research, translational medicine and genome-editing. 

The company is a trusted supplier of genetically-defined cell lines, reporter gene assay kits, genomic reference standards and contract research services to many hundreds of organizations engaged in bio-pharmaceutical process optimization; drug discovery & development and clinical diagnostic development.   

Under the guidance of CEO and President Dr Darrin M Disley since September 2007, the company has made remarkable commercial progress and is one of the fastest growing biotechnology companies in Europe.

The company has attracted a high-quality investor base including , , , , Providence Investment Company Ltd and private investors Dr Jonathan Milner, Mr David Evans, Mr Peter Collins, and Mr David Cleevely.

The growth of the company is reflected in a 100X increase the valuation obtained for its Seed Investment Round in March 2008. The company has provided part-exit opportunities for its early shareholders and investors including an 11-fold return on an initial investment made by .